Recruiting
1280-0022 Xenera-1: A multi-centre, double-blind, placebo-controlled,randomised phase II trial to compare efficacy of xentuzumab incombination with everolimus and exemestane versus everolimus andexemestane in post-menopausal women with HR+ / HER2-metastatic breast cancer and non-visceral disease
A phase II, multicenter, open-label, two-cohort, noncomparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant, hormone receptor (HR) positive, HER2- negative advanced breast cancer (aBC), who have progressed on or after CDK 4/6 inhibitor treatment (BYLieve)
Carrick Therapeutics: CT7001_002: A Phase 1/2 Study of CT7001 in Combination with Fulvestrant in Patients with Metastatic or Locally Advanced Hormone-Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer:
G1 Therapeutics G1T48-01: A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability,Pharmacokinetics, and Preliminary Antitumor Activity of Ascending Doses of G1T48 inWomen with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Genentech: WO41554: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-0077 PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PIK3CA-MUTANT HORMONE RECEPTOR POSITIVE, HER2 NEGATIVE BREAST CANCER: